The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1351
A New Botulinum Toxin (Xeomin) for Cervical Dystonia and Blepharospasm
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved incobotulinumtoxinA (Xeomin – Merz) for treatment of cervical dystonia and blepharospasm in adults. It has been commercially available in Germany since 2005. Several formulations of botulinum toxin type A (Botox; Dysport) and type B (Myobloc) are already marketed for treatment of cervical dystonia. Botox is also approved for treatment of blepharospasm.1

CERVICAL DYSTONIA — Also called spasmodic torticollis, cervical dystonia is characterized by sustained or intermittent, often painful, involuntary muscle contractions of the neck and shoulders. Botulinum toxin is now the standard treatment.2 Alternatives include physical therapy, muscle relaxants, anticholinergic drugs and surgical denervation.

BLEPHAROSPASM — Blepharospasm is a focal dystonia characterized by involuntary sustained muscle ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A New Botulinum Toxin (Xeomin) for Cervical Dystonia and Blepharospasm
Article code: 1351b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian